AOD-9604

Fat LossGH C-terminal fragment analogExperimental

Modified C-terminal hGH fragment studied for lipolysis without GH-receptor growth effects. Not FDA-approved. WADA prohibits GH fragments including AOD-9604 (S2).

Calculate Dose

For research use only.

Key Facts

CAS: 221231-10-3
Molecular Weight (MW): 1815.1 g/mol
Half-life: ~20-30 minutes
Unit: mcg
Administration Route: Subcutaneous
Frequency: 1-2x daily
Last updated: 8/23/2026
Targets: Adipose lipolytic pathways

Overview

Modified C-terminal hGH fragment studied for lipolysis without GH-receptor growth effects. Not FDA-approved. WADA prohibits GH fragments including AOD-9604 (S2).

Protocol

Dosage Range: 250-500 mcg per day
Frequency: 1-2x daily
Cycle: 8-12 weeks on, 4 weeks off
Administration Route: Subcutaneous
Reconstitution Guide: 3 mL BAC water for 5 mg vial

Science

Mechanism of Action

C-terminal GH fragment analog investigated for adipose lipolysis via pathways distinct from full-length GH receptor activation; human obesity trials did not support approval.